These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25584000)

  • 1. Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung cancer.
    Owonikoko TK; Ramalingam SS
    J Clin Oncol; 2015 Feb; 33(6):534-6. PubMed ID: 25584000
    [No Abstract]   [Full Text] [Related]  

  • 2. Docetaxel in advanced non-small cell lung cancer.
    Wakelee H; Ramalingam S; Belani CP
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):13-24. PubMed ID: 15757434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [AIOM Conference 2004. Revision of the role of docetaxel in non-small cell lung cancer].
    Gamucci T; Mansueto G
    Tumori; 2004; 90(6):22-9. PubMed ID: 15762374
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
    Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
    Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Docetaxel and novel strategies in the treatment of NSCLC].
    Longo F; Mansueto G
    Tumori; 2005; 91(6):suppl 11-22. PubMed ID: 16457162
    [No Abstract]   [Full Text] [Related]  

  • 6. Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer.
    Zhang K; Qin H; Pan F; Liu E; Liang H; Ruan Z
    Med Sci Monit; 2014 Dec; 20():2830-6. PubMed ID: 25548985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Singh N; Aggarwal AN
    Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer].
    Gu LP; Shen SP; Chen ZW
    Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):939-42. PubMed ID: 21223805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
    Kris MG; Millward M
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):1-2. PubMed ID: 10437742
    [No Abstract]   [Full Text] [Related]  

  • 10. Lung cancer: Squiring immunotherapy to CheckMate.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Aug; 12(8):436. PubMed ID: 26122186
    [No Abstract]   [Full Text] [Related]  

  • 11. Balancing Benefit, Risk, and Time to New Cancer Therapies.
    West HJ
    JAMA Oncol; 2016 Jan; 2(1):122. PubMed ID: 26468768
    [No Abstract]   [Full Text] [Related]  

  • 12. Nedaplatin: a new platinum for squamous lung cancer?
    Wu Y; Spicer J
    Lancet Oncol; 2015 Dec; 16(16):1573-4. PubMed ID: 26522336
    [No Abstract]   [Full Text] [Related]  

  • 13. Taxanes, past, present, and future impact on non-small cell lung cancer.
    Joshi M; Liu X; Belani CP
    Anticancer Drugs; 2014 May; 25(5):571-83. PubMed ID: 24463482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design.
    Garon EB; Cao D; Alexandris E; John WJ; Yurasov S; Perol M
    Clin Lung Cancer; 2012 Nov; 13(6):505-9. PubMed ID: 22853980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of docetaxel (Taxotere) in non-small cell lung cancer.
    Kris MG; Miller VA; Ng KK; Grant SC
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
    [No Abstract]   [Full Text] [Related]  

  • 16. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
    Kotsakis A; Matikas A; Koinis F; Kentepozidis N; Varthalitis II; Karavassilis V; Samantas E; Katsaounis P; Dermitzaki EK; Hatzidaki D; Mavroudis D; Georgoulias V
    Br J Cancer; 2016 Sep; 115(7):784-8. PubMed ID: 27607471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel in the management of advanced non-small cell lung cancer.
    Miller VA
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.